Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Delayed Quote USD

ABVC BioPharma, Inc. (ABVC)

Compare
1.3200
+0.2600
+(24.53%)
At close: April 1 at 4:00:01 PM EDT
1.3200
0.00
(0.00%)
After hours: April 1 at 7:58:06 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
509.7880
152.4300
969.7830
355.7970
483.0450
Cost of Revenue
139.9690
302.0370
286.4150
5.0860
18.7160
Gross Profit
369.8190
-149.6070
683.3680
350.7110
464.3290
Operating Expense
6,702.5130
8,066.9020
15,797.7800
11,695.7810
8,970.1050
Operating Income
-6,332.6940
-8,216.5090
-15,114.4120
-11,345.0700
-8,505.7760
Net Non Operating Interest Income Expense
-2,154.6150
-2,307.8590
-106.1510
-184.0140
-333.9870
Other Income Expense
-165.6530
-129.9140
-294.0330
318.2570
-1,974.1730
Pretax Income
-8,652.9620
-10,654.2820
-15,514.5960
-11,210.8270
-10,813.9360
Tax Provision
64.7710
256.0060
797.7780
825.0240
-220.3520
Net Income Common Stockholders
-8,243.1160
-10,515.6560
-16,423.2390
-12,838.8130
-9,791.1640
Diluted NI Available to Com Stockholders
-8,243.1160
-10,515.6560
-16,423.2390
-12,838.8130
-9,791.1640
Basic EPS
-0.81
-2.43
-5.20
-5.10
-5.00
Diluted EPS
-0.81
-2.43
-5.20
-5.10
-5.00
Basic Average Shares
10,042.1140
4,335.6500
3,166.4660
2,505.3520
1,971.5550
Diluted Average Shares
10,042.1140
4,335.6500
3,166.4660
2,505.3520
1,971.5550
Total Operating Income as Reported
-6,332.6940
-8,216.5090
-15,114.4120
-11,705.9680
-8,505.7760
Total Expenses
6,842.4820
8,368.9390
16,084.1950
11,700.8670
8,988.8210
Net Income from Continuing & Discontinued Operation
-8,243.1160
-10,515.6560
-16,423.2390
-12,838.8130
-9,791.1640
Normalized Income
-8,150.4577
-10,358.2896
-16,125.3821
-12,953.0376
-7,661.6451
Interest Income
112.9340
185.4810
187.8170
43.1960
71.0450
Interest Expense
2,267.5490
2,493.3400
293.9680
227.2100
405.0320
Net Interest Income
-2,154.6150
-2,307.8590
-106.1510
-184.0140
-333.9870
EBIT
-6,385.4130
-8,160.9420
-15,220.6280
-10,983.6170
-10,408.9040
EBITDA
-6,356.2260
-8,132.4110
-15,196.8290
-10,971.6240
-10,371.7620
Reconciled Cost of Revenue
139.9690
302.0370
286.4150
5.0860
18.7160
Reconciled Depreciation
29.1870
28.5310
23.7990
11.9930
37.1420
Net Income from Continuing Operation Net Minority Interest
-8,243.1160
-10,515.6560
-16,423.2390
-12,838.8130
-9,791.1640
Total Unusual Items Excluding Goodwill
-117.2890
-199.1980
-377.0340
156.4720
-2,173.8140
Total Unusual Items
-117.2890
-199.1980
-377.0340
156.4720
-2,173.8140
Normalized EBITDA
-6,238.9370
-7,933.2130
-14,819.7950
-11,128.0960
-8,197.9480
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0
Tax Effect of Unusual Items
-24.6307
-41.8316
-79.1771
42.2474
-44.2951
12/31/2020 - 11/10/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ZVSA ZyVersa Therapeutics, Inc.
0.5875
-6.54%
 
PALI Palisade Bio, Inc.
0.6698
-1.62%
 
SPRC SciSparc Ltd.
0.2809
-5.74%
 
LIXT Lixte Biotechnology Holdings, Inc.
1.1950
-1.24%
 
RNXT RenovoRx, Inc.
0.9600
-3.03%
 
REVB Revelation Biosciences, Inc.
2.6000
-1.14%
 
ENSC Ensysce Biosciences, Inc.
2.5000
-2.34%
 
NKGN NKGen Biotech, Inc.
0.1913
+6.28%
 
SILO Silo Pharma, Inc.
1.1300
-3.42%
 
CMND Clearmind Medicine Inc.
1.0300
-0.96%